| Project/Area Number |
16K18971
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Fukuoka University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2016-04-01 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | プロドラッグ / NAFLD / 脂肪肝 / 医療薬剤学 |
|---|
| Outline of Final Research Achievements |
2R-γ-Tocotrienyl N, N-dimethylglycinate hydrochloride (γ-T3DMG) is a prodrug of γ-tocotrienol (γ-T3) with high water-solubility and stability to oxidation, it could effectively deliver γ-T3 in the rat liver. The present study investigated the therapeutic effects of γ-T3DMG on a fatty liver model in vitro and in vivo. γ-T3DMG significantly suppressed levels of triglyceride (TG) and total cholesterol on a fatty liver model using HepG2 cells. In addition, γ-T3DMG significantly suppressed plasma ALT activities and plasma TG concentrations in TSOD mice with spontaneously developed obesity. These results indicated that γ-T3DMG had a beneficial effect on hepatic steatosis, thus could be a promising candidate for the treatment of NAFLD.
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究室で開発した2R-γ-Tocotrienyl N,N-dimethylglycinate hydrochloride (γ-T3DMG) はγ-トコトリエノールを肝臓へ効率的に送達する水溶性プロドラッグである。本研究ではin vitro及びin vivo脂肪肝モデルを用いてγ-T3DMGが優れた脂肪肝抑制効果を有することを明らかにした。よって本研究によりγ-T3DMGを新規のNAFLD治療薬として臨床応用するための基盤を確立した。
|
